- Analysis
- Barani Krishnan
- 32
ABI SAB Group Holding Limited engages in the production and sale of beer worldwide. The company was formerly known as SABMiller Limited and changed its name to ABI SAB Group Holding Limited in June 2017. The company was founded in 1895 and is based in London, the United Kingdom. ABI SAB Group Holding Limited operates as a subsidiary of ABI UK Holding 2 Limited.
Pioneering T1D Treatment | SAB Biotherapeutics advances SAB-142, a novel anti-thymocyte globulin, through clinical trials with promising safety profile for delaying type 1 diabetes onset |
Market Potential | Analysts project SAB-142 sales to reach $75 million at 2029 launch, growing to $200 million by 2030, signaling strong commercial prospects |
Regulatory Milestones | FDA clearance for SAB-142's IND application paves way for U.S. clinical trials, with additional regulatory filings planned to support Phase 2b development |
Investment Outlook | H.C. Wainwright maintains a Buy rating with a $6.00 price target, highlighting potential upside from current $3.45 share price and $40 million market cap |